TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01318811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilute unfractionated heparin
Description: Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard concentration unfractionated heparin
Description: Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
Study: NCT03259165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrates
Description: For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~2. SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to \< 120 mmHg)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm.
Study: NCT03469193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal PUC implanted with mechanical ancillary
Description: The control group consists of patients operated with a mechanical ancillary (reference surgery in our department). In this technique, bone sections are made with a standardized ancillary (manually adjusted bone cutting guides), according to preoperative radiological planning. The positioning of the implants is done manually and controlled by the placement of test implants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal PUC implanted with robotic assistance
Description: Patients are operated by robotics (surgery that we want to develop systematically in our service). 3D modeling of the knee allows the operator to perform a dynamic planning taking into account the reducibility of the deformation and the model of the implant. The operator can position the implants in three dimensions of the space without difficulty. This makes it possible to visualize, before the bone resections, the angular correction obtained between 0 and 130° flexion and alignment of the prosthesis by visualizing the contact points between the two implants. Bone resections will be performed using a guided retro bone drill. The system retracts more or less the cutter according to the bone thickness to be removed. This technique requires the insertion of two threaded plugs in the tibia and two in the femur to position the sensors that will allow the acquisition of anatomical landmarks of the lower limb and then 3D modeling
Study: NCT00576693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracranial angioplasty and stenting
Description: intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive medical management
Description: intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
Study: NCT03242759

Intervention type: DRUG
Intervention: nintedanib
Description: Drug

Intervention type: DRUG
Intervention: pirfenidone
Description: Drug
Study: NCT03259165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loop Diuretics
Description: For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. Patients receive 1 inch topical nitropaste~2. IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm.
Study: NCT05805540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold-water immersion
Description: Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protein-carbohydrates supplementation
Description: Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water. Subject sat for 25 minutes until all recovery methods were completed.
Study: NCT02412358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toothbrush
Study: NCT04003363

Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Study: NCT02600247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Description: Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Study: NCT04366271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal cells
Description: 1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Best treatment option for COVID-19 according to investigator criteria
Study: NCT02600247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Description: Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Study: NCT00681486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
Study: NCT04162899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
Study: NCT04239560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boron-based Gel (Fibore)
Description: During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
Study: NCT03280550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Study: NCT00976573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT02585180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tubes allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
Study: NCT02531334

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TA-65
Description: 2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TA-65
Description: 2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
Study: NCT02554188

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza (flu) vaccine
Description: Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older
Study: NCT04404283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 20 mg given by mouth (orally) daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 20 mg given by mouth (orally) daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered via intravenous infusion every 3 weeks
Study: NCT01722734

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text message reminders
Description: Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text message reminders
Description: Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
Study: NCT01682720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SOF
Description: Placebo to match SOF administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match RBV
Description: Placebo to match RBV administered orally in a divided daily dose
Study: NCT03989687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Triage
Description: glass ionomer sealant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isolation
Description: rubber dam or cotton roll isolation
Study: NCT00863629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
Study: NCT05805540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active recovery
Description: Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects drank a water-based drink and sweetener. Subject sat for 25 minutes until all recovery methods were completed.
Study: NCT02617420

Intervention type: DEVICE
Intervention: Propeller Health Monitoring Device
Study: NCT02430636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT03274310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational text messages
Description: Educational text message about ways to decrease household transmission of influenza and other respiratory infections
Study: NCT04025372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH Agonist
Description: In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
Study: NCT03414970

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT
Study: NCT04625855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Description: TBPM-PI-HBr (3 x 200 mg tablets) once
Study: NCT03473743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Participants will receive cetrelimab by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Participants will receive cetrelimab by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
Study: NCT04319094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social interaction
Description: Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
Study: NCT01016483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Study: NCT03930810

Intervention type: PROCEDURE
Intervention: Surgical biliary diversion
Description: Surgical interruption of enterohepatic circulation
Study: NCT03497117

Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Clearance Index
Description: To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.